This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

6 Aug 2012

US Dominates Market for Bipolar Disorder Drugs

The vast majority of major-market sales of bipolar disorder drugs are recorded in the US.

The US accounted for almost 90 per cent of major-market sales of drugs for bipolar disorder in 2011, new figures show.


A report by research and advisory firm Decision Resources confirms the US' dominance of sales of bipolar disorder therapies, with sales set to remain stable in Europe and Japan over the coming years.


Major-market sales of all therapies for the condition are likely to fall from $6.3 billion in 2011 to around $4 billion in 2021, with generic competition within atypical antipsychotics causing a decline in the market.


Among this class of drugs, total sales are expected to fall to just over $3 billion in the US, France, Germany, Italy, Spain, the U

Related News